Effect of antimicrobial agents on the ecological balance of human microflora

Lancet Infectious Diseases

Volumn 1, Issue 2, 2001, Pages 101-114

  Sullivan, Åsa ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT;

BACTERIUM; DRUG EFFECT; ECOLOGY; GROWTH, DEVELOPMENT AND AGING; HUMAN; INTESTINE; MICROBIOLOGY; OROPHARYNX; REVIEW;

ANTI-BACTERIAL AGENTS; BACTERIA; ECOLOGY; HUMANS; INTESTINES; OROPHARYNX;

EID: 0035468838     PISSN: 14733099     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1473-3099(01)00066-4     Document Type: Review

References (65)

1. van der Waaij D., Nord C.E. Development and persistence ofmulti-resistance to antibiotics in bacteria; an analysis and a new approach to this urgent problem. Int J Antimicrob Agents. 16:2000;191-197.
2. Vollaard E.J., Clasener H.A.L. Colonization resistance. Minireview. Antimicrob Agents Chemother. 38:1994;409-414.
3. Edlund C., Nord C.E. Ecological impact of antimicrobial agents on human intestinal microflora. Review article. Alpe Adria Microbiol J. 3:1993;137-164.
4. Adamsson I., Edlund C., Sjöstedt S., Nord C.E. Comparativeeffects of cefadroxil and phenoxymethylpenicillin on thenormal oropharyngeal and intestinal microflora. Infection. 25:1997;154-158.
5. Sjöberg I., Grahn E., Håkansson S., Holm S.E. Influence of phenoxymethylpenicillin on the vaginal ecosystem. Gynecol Obstet Invest. 33:1992;42-46.
6. Black F., Einarsson K., Lidbeck A., Orrhage K., Nord C.E. Effect of lactic acid producing bacteria on the human intestinal microflora during ampicillin treatment. Scand J Infect Dis. 23:1991;247-254.
7. Christensson B., Nilsson-Ehle I., Ljungberg B., et al. A randomized multicenter trial to compare the influence of cefaclor and amoxycillin on the colonization resistance of the digestive tract in patients with lower respiratory tract infection. Infection. 19:1991;208-215.
8. Brismar B., Edlund C., Nord C.E. Impact of cefpodoxime proxetil and amoxicillin on the normal oral and intestinal microflora. Eur J Clin Microbiol Infect Dis. 12:1993;714-719.
9. Floor M., van Akkeren F., Rozenberg-Arska M., et al. Effect of loracarbef and amoxicillin on the oropharyngeal and intestinal microflora of patients with bronchitis. Scand J Infect Dis. 26:1994;191-197.
10. Edlund C., Stark C., Nord C.E. The relationship between an increase in β-lactamase activity after oral administration of three new cephalosporins and protection against intestinal ecological disturbances. J Antimicrob Chemother. 34:1994;127-138.
11. Stark C.A., Adamsson I., Edlund C., et al. Effects of omeprazole and amoxycillin on the human oral and gastrointestinal microflora in patients with Helicobacter pylori infection. J Antimicrob Chemother. 38:1996;927-939.
12. Adamsson I., Edlund C., Seensalu R., Sjöstedt S., Nord C.E. The normal gastric microflora and Helicobacter pylori; before, during and after treatment with omeprazole and amoxycillin. Clin Microbiol Infect. 4:1998;308-315.
13. Lidefelt K.J., Bollgren I., Nord C.E. Changes in periurethral microflora after antimicrobial drugs. Arch Dis Child. 66:1991;683-685.
14. Lund B., Edlund C., Rynnel-Dagöö B., Lundgren Y., Sterner J., Nord C.E. Ecological effects on the oro- and nasopharyngeal microflora in children after treatment of acute otitis media with cefuroxime axetil or coamoxyclavulanate as suspensions. Clin Microbiol Infect. 7:2001;230-237.
15. Lode H, von der Höh N, Ziege S, Borner K, Nord CE. Ecological effects of linezolid versus amoxycillin/clavulanic acid on the normal intestinal microflora. Scand J Infect Dis (in press).
16. Nord C.E., Brismar B., Kasholm-Tengve B., Tunevall G. Effect of piperacillin/tazobactam treatment on human bowel microflora. J Antimicrob Chemother. 31:((suppl A)):1993;61-65.
17. Sullivan Å., Edlund C., Svenungsson B., Emtestam L., Nord C.E. Effect of perorally administered pivmecillinam on the normal oropharyngeal, intestinal and skin microflora. J Chemother. 13:2001;299-308.
18. Freeman J., Wilcox M.H. Antibiotics and Clostridium difficile. Microbes Infect. 1:1999;377-384.
19. Bächer K., Schaeffer M., Lode H., Nord C.E., Borner K., Koeppe P. Multiple dose pharmacokinetics, safety, and effects on faecal microflora, of cefepime in healthy volunteers. J Antimicrob Chemother. 30:1992;365-375.
20. Knothe H., Schäfer V., Sammann A., Badian M., Shah P.M. Influence of cefpirome on pharyngeal and faecal flora aftersingle and multiple intravenous administrations of cefpirome to healthy volunteers. J Antimcrob Chemother. 29:((suppl A)):1992;81-86.
21. Welling G.W., Meijer-Severs G.J., Helmus G., et al. The effectof ceftriaxone on the anaerobic bacterial flora and the bacterial enzymatic activity in the intestinal tract. Infection. 19:1991;313-316.
22. de Vries-Hospers H.G., Tonk R.H.J., van der Waaij D. Effect of intramuscular ceftriaxone on aerobic oral and faecal flora of 11 healthy volunteers. Scand J Infect Dis. 23:1991;625-633.
23. Cavallaro V., Catania V., Bonaccorso R., et al. Effect of a broad-spectrum cephalosporin on the oral and intestinal microflora in patients undergoing colorectal surgery. J Chemother. 4:1992;82-87.
24. Vogel F, Ochs HR, Wettich K, et al. Effect of step-down therapy of ceftriaxone plus loracarbef versus parenteral therapy of ceftriaxone on the intestinal microflora in patients with community-acquired pneumonia. Clin Microbiol Infect (in press).
25. Novelli A., Mazzei T., Fallani S., Dei R., Cassetta M.I., Conti S. Betalactam therapy and intestinal flora. J Chemother. 7:(suppl 1):1995;25-32.
26. Orrhage K., Sjöstedt S., Nord C.E. Effect of supplements with lactic acid bacteria and oligofructose on the intestinal microflora during administration of cefpodoxime proxetil. J Antimicrob Chemother. 46:2000;603-611.
27. Lode H., Müller C., Borner K., Nord C.E., Koeppe P. Multiple-dose pharmacokinetics of cefprozil and its impact on intestinal flora of volunteers. Antimicrob Agents Chemother. 36:1992;144-149.
28. Brismar B., Edlund C., Nord C.E. Effect of ceftibuten on the normal intestinal microflora. Infection. 21:1993;373-375.
29. Edlund C., Barkholt L., Olsson-Liljequist B., Nord C.E. Effect of vancomycin on intestinal flora of patients who previously received antimicrobial therapy. Clin Infect Dis. 25:1997;729-732.
30. Edlund C., Brismar B., Sakamoto H., Nord C.E. Impact of cefuroxime-axetil on the normal intestinal microflora. Microbiol Ecol in Health Dis. 6:1993;185-189.
31. Nord C.E., Grahnen A., Eckernäs S.Å. Effect of loracarbef on the normal oropharyngeal and intestinal microflora. Scand J Infect Dis. 23:1991;255-260.
32. Bergan T., Nord C.E., Thorsteinsson S.B. Effect of meropenem on the intestinal microflora. Eur J Clin Microbiol Infect Dis. 10:1991;524-527.
33. Nakashima M., Uematsu T., Kosuge K., Nakagawa S., Hata S., Sanada M. Pharmacokinetics and safety of BO-2727, a new injectable 1-β-methyl carbapenem antibiotic, and its effect on the faecal microflora in healthy male volunteers. J Antimicrob Chemother. 33:1994;987-998.
34. Orrhage K., Brismar B., Nord C.E. Effect of supplements with Bifidobacterium longum and Lactobacillus acidophilus on the intestinal microbiota during administration of clindamycin. Microbiol Ecol in Health Dis. 7:1994;17-25.
35. Scanvic-Hameg A, Chachaty E, Rey J, et al. Impact of Quinupristin/Dalfopristin (RP59500) on the fecal microflora in healthy volunteers. J Antimicrob Chemother (in press).
36. Beyer G., Hiemer-Bau M., Ziege S., Edlund C., Lode H., Nord C.E. Impact of moxifloxacin versus clarithromycin on normal oropharyngeal microflora. Eur J Clin Microbiol Infect Dis. 19:2000;548-550.
37. Brismar B., Edlund C., Nord C.E. Comparative effects of clarithromycin and erythromycin on the normal intestinal microflora. Scand J Infect Dis. 23:1991;635-642.
38. Edlund C., Beyer G., Hiemer-Bau M., Ziege S., Lode H., Nord C.E. Comparative effects of moxifloxacin and clarithromycin on the normal intestinal microflora. Scand J Infect Dis. 32:2000;81-85.
39. Edlund C., Alván G., Barkholt L., Vacheron F., Nord C.E. Pharmacokinetics and comparative effects of telithromycin (HMR 3647) and clarithromycin on the oropharyngeal and intestinal microflora. J Antimicrob Chemother. 46:2000;741-749.
40. Eckernäs S.Å., Grahnén A., Nord C.E. Impact of dirithromycin on the normal oral and intestinal microflora. Eur J Clin Microbiol Infect Dis. 10:1991;688-692.
41. Pecquet S., Chachaty E., Tancrède C., Andremont A. Effects of roxithromycin on fecal bacteria in human volunteers and resistance to colonization in gnotobiotic mice. Antimicrob Agents Chemother. 35:1991;548-552.
42. Lund B., Edlund C., Barkholt L., Nord C.E., Tvede M., Poulsen R.L. Impact on human intestinal microflora of an Enterococcus faecium probiotic and vancomycin. Scand J Infect Dis. 32:2000;627-632.
43. Van der Auwera P., Pensart N., Korten V., Murray B.E., Leclercq R. Influence of oral glycopeptides on the fecal flora of human volunteers: selection of highly glycopeptide-resistant enterococci. J Infect Dis. 173:1996;1129-1136.
44. Nord C.E. Ecological impact of narrow spectrum antimicrobial agents compared to broad spectrum agents on the human intestinal microflora. Nord C.E., Heidt P.J., Rusch V.C., van der Waaij D. Old Herborn university seminar monograph: Consequences of antimicrobial therapy for the composition of the microflora of the digestive tract. 1993;8-19 Institute for Microbiology and Biochemistry, Herborn.
45. Adamsson I., Nord C.E., Lundquist P., Sjöstedt S., Edlund C. Comparative effects of omeprazole, amoxycillin plus metronidazole versus omeprazole, clarithromycin plus metronidazole on the oral, gastric and intestinal microflora in Helicobacter pylori-infected patients. J Antimicrob Chemother. 44:1999;629-640.
46. Mavromanolakis E., Maraki S., Samonis G., Tselentis Y., Cranidis A. Effect of norfloxacin, trimethoprim-sulfamethoxazole and nitrofurantoin on fecal flora of women with recurrent urinary tract infections. J Chemother. 9:1997;203-207.
47. Edlund C., Lindqvist L., Nord C.E. Norfloxacin binds to human fecal material. Antimicrob Agents Chemother. 32:1988;1869-1874.
48. Fredricsson B., Englund K., Nord C.E., Weintraub L. Couldbacterial vaginosis be due to the competitive suppression of lactobacilli by aerobic microorganisms. Gynecol Obstet Invest. 33:1992;119-123.
49. van de Leur J.J.J.P.M., Vollaard E.J., Janssen A.J.H.M., Dofferhoff A.S.M. Influence of low dose ciprofloxacin on microbial colonization of the digestive tract in healthy volunteers during normal and during impaired colonization resistance. Scand J Infect Dis. 29:1997;297-300.
50. Wiström J., Gentry L.O., Palmgren A.C., et al. Ecological effects of short-term ciprofloxacin treatment of travellers' diarrhoea. J Antimicrob Chemother. 30:1992;693-706.
51. Borzio M., Salerno F., Saudelli M., Galvagno D., Piantoni L., Fragiacomo L. Efficacy of oral ciprofloxacin as selective intestinal decontaminant in cirrhosis. Ital J Gastroenterol Hepatol. 29:1997;262-266.
52. Krueger W.A., Ruckdeschel G., Unertl K. Influence of intravenously administered ciprofloxacin on aerobic intestinal microflora and fecal drug levels when administered simultaneously with sucralfate. Antimcrob Agents Chemother. 41:1997;1725-1730.
53. Oh H., Nord C.E., Barkholt L., Hedberg M., Edlund C. Ecological disturbances in intestinal microflora caused by clinafloxacin, an extended-spectrum quinolone. Infection. 28:2000;272-277.
54. Edlund C., Nord C.E. Ecological effect of gatifloxacin on the normal human intestinal microflora. J Chemother. 11:1999;50-53.
55. Garcia-Calvo G., Molleja A., Giménez M.J., et al. Effects of single oral doses of gemifloxacin (320 milligrams) versus trovafloxacin(200 milligrams) on fecal flora in healthy volunteers. Antimicrob Agents Chemother. 45:2001;608-611.
56. Barker P.J., Sheehan R., Teillol-Foo M., Palmgren A.-C., Nord C.E. Impact of gemifloxacin on the normal human intestinal microflora. J Chemother. 13:2001;47-51.
57. Edlund C., Sjöstedt S., Nord C.E. Comparative effects of levofloxacin and ofloxacin on the normal oral and intestinal microflora. Scand J Infect Dis. 29:1997;383-386.
58. Inagaki Y., Nakaya R. The effect of levofloxacin, an optically-active isomer of ofloxacin, on fecal microflora in human volunteers. Jpn J Antibiot. 45:1992;241-252.
59. Marco F., Giménez M.J., Jiménez de Anta M.T., et al. Comparison of rufloxacin and norfloxacin effects on faecal flora. J Antimicrob Chemother. 35:1995;895-901.
60. Vollaard E.J., Clasener H.A.L., Janssen A.J.H.M. Influence of pefloxacin on microbial colonization resistance in healthy volunteers. Eur J Clin Microbiol Infect Dis. 11:1992;257-260.
61. D'Antonio D., Pizzigallo E., Iacone A., et al. The impact of rufloxacin given as prophylaxis to patients with cancer on their oral and faecal microflora. J Antimicrob Chemother. 38:1996;839-847.
62. Inagaki Y., Yamamoto N., Chida T., Okamura N., Tanaka M. The effect of DU-6859a, a new potent fluoroquinolone,on fecal microflora in human volunteers. Jpn J Antibiot. 48:1995;368-379.
63. Ritz M., Lode H., Faßbender M., Borner K., Koeppe P., Nord C.E. Multiple-dose pharmacokinetics of sparfloxacin and its influence on fecal flora. Antimicrob Agents Chemother. 38:1994;455-459.
64. van Nispen C.H.M., Hoepelman A.I.M., Rozenberg-Arska M., Verhoef J., Purkins L., Willavize S.A. A double-blind, placebo-controlled, parallel group study of oral trovafloxacin on bowel microflora in healthy male volunteers. Am J Surg. 176:(suppl 6A):1998;27-31.
65. Nord CE, Gajjar DA, Grasela DM. Ecological impact of BMS-284756 on the normal intestinal microflora. Clin Microbiol Infect(in press).